Arterra Bioscience SpA (MIL:ARBS) Cash-to-Debt : 9.99 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Arterra Bioscience SpA Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arterra Bioscience SpA's cash to debt ratio for the quarter that ended in Jun. 2024 was 9.99.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Arterra Bioscience SpA could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Arterra Bioscience SpA's Cash-to-Debt or its related term are showing as below:

MIL:ARBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4 Med: 6.21 Max: 12.25
Current: 9.99

During the past 7 years, Arterra Bioscience SpA's highest Cash to Debt Ratio was 12.25. The lowest was 0.40. And the median was 6.21.

MIL:ARBS's Cash-to-Debt is ranked better than
53.94% of 1485 companies
in the Biotechnology industry
Industry Median: 7.49 vs MIL:ARBS: 9.99

Arterra Bioscience SpA Cash-to-Debt Historical Data

The historical data trend for Arterra Bioscience SpA's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Arterra Bioscience SpA Cash-to-Debt Chart

Arterra Bioscience SpA Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.66

5.60

7.84

12.25

9.55

Arterra Bioscience SpA Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial									9.93	12.25	11.51	9.55	9.99

Competitive Comparison of Arterra Bioscience SpA's Cash-to-Debt

For the Biotechnology subindustry, Arterra Bioscience SpA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arterra Bioscience SpA's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Arterra Bioscience SpA's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Arterra Bioscience SpA Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Arterra Bioscience SpA's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.686	/	(0.086	+	0.3)
	=	9.55

Arterra Bioscience SpA's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.427	/	(0.043	+	0.3)
	=	9.99

Arterra Bioscience SpA (MIL:ARBS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Arterra Bioscience SpA Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Arterra Bioscience SpA's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Arterra Bioscience SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arterra Bioscience SpA (MIL:ARBS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

via Benedetto Brin, 69, Napoli, ITA, 80142

Website

https://www.arterrabio.it

Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.

Arterra Bioscience SpA Headlines

No Headlines